Home Healthcare Biotechnology Rare Biomarkers Specimen Collection and Stabilization Market

Rare Biomarkers Specimen Collection and Stabilization Market Size, Share & Trends Analysis Report By Type (Circulating Cell-Free DNA (ccfDNA), Circulating Tumor Cells (CTCs), Exosomes/Extracellular Vesicles), By Product (Isolation Kits & Reagents, Blood Collection Tubes, Systems), By Application (Non-Invasive Prenatal Testing (NIPT), Oncology, Pharmacogenomics, Transplant Rejection, Cardiovascular Diseases, Others), By End-Users (Hospitals, Perinatal Clinics, Diagnostics Laboratories, Research Institutes, Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Dhanashri B | Format:
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Rare Biomarkers Specimen Collection and Stabilization Market, By Type 2022-2034 (USD MILLION/ Units)
    1. Circulating Cell-Free DNA (ccfDNA)
    2. Circulating Tumor Cells (CTCs)
    3. Exosomes/Extracellular Vesicles
  2. Rare Biomarkers Specimen Collection and Stabilization Market, By Product 2022-2034 (USD MILLION/ Units)
    1. Isolation Kits & Reagents
    2. Blood Collection Tubes
    3. Systems
  3. Rare Biomarkers Specimen Collection and Stabilization Market, By Application 2022-2034 (USD MILLION/ Units)
    1. Non-Invasive Prenatal Testing (NIPT)
    2. Oncology
    3. Pharmacogenomics
    4. Transplant Rejection
    5. Cardiovascular Diseases
    6. Others
  4. Rare Biomarkers Specimen Collection and Stabilization Market, By End-Users 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Perinatal Clinics
    3. Diagnostics Laboratories
    4. Research Institutes
    5. Others
  5. Regional Rare Biomarkers Specimen Collection and Stabilization Market
    1. North America
      1. North America Rare Biomarkers Specimen Collection and Stabilization Market By Type 2022-2034 (USD MILLION/ Units)
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
      2. North America Rare Biomarkers Specimen Collection and Stabilization Market By Product 2022-2034 (USD MILLION/ Units)
        1. Isolation Kits & Reagents
        2. Blood Collection Tubes
        3. Systems
      3. North America Rare Biomarkers Specimen Collection and Stabilization Market By Application 2022-2034 (USD MILLION/ Units)
        1. Non-Invasive Prenatal Testing (NIPT)
        2. Oncology
        3. Pharmacogenomics
        4. Transplant Rejection
        5. Cardiovascular Diseases
        6. Others
      4. North America Rare Biomarkers Specimen Collection and Stabilization Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Perinatal Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
        5. Others
      5. U.S.
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      6. Canada
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
    2. Europe
      1. Europe Rare Biomarkers Specimen Collection and Stabilization Market By Type 2022-2034 (USD MILLION/ Units)
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
      2. Europe Rare Biomarkers Specimen Collection and Stabilization Market By Product 2022-2034 (USD MILLION/ Units)
        1. Isolation Kits & Reagents
        2. Blood Collection Tubes
        3. Systems
      3. Europe Rare Biomarkers Specimen Collection and Stabilization Market By Application 2022-2034 (USD MILLION/ Units)
        1. Non-Invasive Prenatal Testing (NIPT)
        2. Oncology
        3. Pharmacogenomics
        4. Transplant Rejection
        5. Cardiovascular Diseases
        6. Others
      4. Europe Rare Biomarkers Specimen Collection and Stabilization Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Perinatal Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
        5. Others
      5. U.K.
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      6. Germany
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      7. France
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      8. Spain
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      9. Italy
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      10. Russia
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      11. Nordic
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      12. Benelux
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      13. Rest of Europe
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
    3. APAC
      1. APAC Rare Biomarkers Specimen Collection and Stabilization Market By Type 2022-2034 (USD MILLION/ Units)
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
      2. APAC Rare Biomarkers Specimen Collection and Stabilization Market By Product 2022-2034 (USD MILLION/ Units)
        1. Isolation Kits & Reagents
        2. Blood Collection Tubes
        3. Systems
      3. APAC Rare Biomarkers Specimen Collection and Stabilization Market By Application 2022-2034 (USD MILLION/ Units)
        1. Non-Invasive Prenatal Testing (NIPT)
        2. Oncology
        3. Pharmacogenomics
        4. Transplant Rejection
        5. Cardiovascular Diseases
        6. Others
      4. APAC Rare Biomarkers Specimen Collection and Stabilization Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Perinatal Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
        5. Others
      5. China
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      6. Korea
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      7. Japan
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      8. India
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      9. Australia
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      10. Taiwan
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      11. South East Asia
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      12. Rest of Asia-Pacific
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
    4. Middle East and Africa
      1. Middle East and Africa Rare Biomarkers Specimen Collection and Stabilization Market By Type 2022-2034 (USD MILLION/ Units)
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
      2. Middle East and Africa Rare Biomarkers Specimen Collection and Stabilization Market By Product 2022-2034 (USD MILLION/ Units)
        1. Isolation Kits & Reagents
        2. Blood Collection Tubes
        3. Systems
      3. Middle East and Africa Rare Biomarkers Specimen Collection and Stabilization Market By Application 2022-2034 (USD MILLION/ Units)
        1. Non-Invasive Prenatal Testing (NIPT)
        2. Oncology
        3. Pharmacogenomics
        4. Transplant Rejection
        5. Cardiovascular Diseases
        6. Others
      4. Middle East and Africa Rare Biomarkers Specimen Collection and Stabilization Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Perinatal Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
        5. Others
      5. UAE
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      6. Turkey
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      7. Saudi Arabia
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      8. South Africa
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      9. Egypt
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      10. Nigeria
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      11. Rest of MEA
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
    5. LATAM
      1. LATAM Rare Biomarkers Specimen Collection and Stabilization Market By Type 2022-2034 (USD MILLION/ Units)
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
      2. LATAM Rare Biomarkers Specimen Collection and Stabilization Market By Product 2022-2034 (USD MILLION/ Units)
        1. Isolation Kits & Reagents
        2. Blood Collection Tubes
        3. Systems
      3. LATAM Rare Biomarkers Specimen Collection and Stabilization Market By Application 2022-2034 (USD MILLION/ Units)
        1. Non-Invasive Prenatal Testing (NIPT)
        2. Oncology
        3. Pharmacogenomics
        4. Transplant Rejection
        5. Cardiovascular Diseases
        6. Others
      4. LATAM Rare Biomarkers Specimen Collection and Stabilization Market By End-Users 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Perinatal Clinics
        3. Diagnostics Laboratories
        4. Research Institutes
        5. Others
      5. Brazil
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      6. Mexico
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      7. Argentina
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      8. Chile
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      9. Colombia
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
      10. Rest of LATAM
        1. Circulating Cell-Free DNA (ccfDNA)
        2. Circulating Tumor Cells (CTCs)
        3. Exosomes/Extracellular Vesicles
        4. Isolation Kits & Reagents
        5. Blood Collection Tubes
        6. Systems
        7. Non-Invasive Prenatal Testing (NIPT)
        8. Oncology
        9. Pharmacogenomics
        10. Transplant Rejection
        11. Cardiovascular Diseases
        12. Others
        13. Hospitals
        14. Perinatal Clinics
        15. Diagnostics Laboratories
        16. Research Institutes
        17. Others
Report Details
−
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.